tapebrief
MCK · Q3 2026

MCK · Q4 2026 Earnings

Bullish

McKesson Corporation

Reported May 7, 2026

30-second summary

McKesson closed FY26 with $96.3B Q4 revenue (+6% YoY) and $11.69 Q4 adjusted EPS (+16% YoY), bringing FY26 adjusted EPS to $39.11 — landing in the upper half of the $38.80–$39.20 range raised at Q3, and at the low end of the +12–16% FY revenue growth guide at +12%. Management initiated FY27 adjusted EPS guidance of $43.80–$44.60 (+12–14% YoY), reaffirmed the long-term +13–16% target, and announced a $1.25B strategic minority investment from Apollo into the Medical-Surgical business at a ~$13B enterprise value — a concrete valuation marker on the H2 CY2027 IPO. Oncology & Multispecialty closed FY26 at +31% (in the middle of the +29–33% guide), but the FY27 Oncology revenue guide of +14.5–18.5% signals deceleration as PRISM and Core Ventures comp out.

Headline numbers

EPS

Q4 FY2026

$11.69

Revenue

Q4 FY2026

$96.30B

+6.0% YoY

Gross margin

Q4 FY2026

4.2%

Free cash flow

Q4 FY2026

$3.24B

Operating margin

Q4 FY2026

2.2%

Key financials

Q4 FY2026
MetricQ4 FY2026YoYQ3 FY2026QoQ
Revenue$96.30B+6.0%$106.16B-9.3%
EPS$11.69—$9.34+25.2%
Gross margin4.2%—3.5%+73bps
Operating margin2.2%—1.5%+70bps
Free cash flow$3.24B—$1.10B+194.2%

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Adjusted EPSFY 2026$38.80 to $39.20$39.11in-line (within prior guidance range)Beat
RevenueFY 202612% to 16% growth12% YoY growthat bottom of prior guidance rangeMet
Operating ProfitFY 202613% to 17% growthOperating profit growth not explicitly disclosed in actuals—Missed
North American Pharmaceutical revenue growthFY 202610% to 14%3%-7 to -11 pts below guidanceMissed
North American Pharmaceutical operating profit growthFY 20268% to 12%Not explicitly reported—Missed
Oncology & Multispecialty revenue growthFY 202629% to 33%35%+2 to +6 pts above guidanceBeat
Oncology & Multispecialty operating profit growthFY 202651% to 55%Not explicitly reported—Missed
Prescription Technology Solutions revenue growthFY 20269% to 13%12%in-line (within guidance)Beat
Prescription Technology Solutions operating profit growthFY 202614% to 18%Not explicitly reported—Missed
Free Cash FlowFY 2026$4.4 to $4.8 billion$5.41 billion+$0.61 to +$1.01 billion above guidanceBeat
Share RepurchasesFY 2026approximately $2.5 billion$2.7 billion+$0.2 billion above guidanceBeat

New guidance

MetricPeriodGuideYoY
Adjusted EPSFY 2027$43.80 to $44.60+12% to +14% YoY
North American Pharmaceutical revenue growthFY 2027——

Segment KPIs

Q4 FY2026
SegmentQ4 FY2026YoY
North American Pharmaceutical$79.12B+3.0%
Oncology & Multispecialty$12.71B+35.0%
Prescription Technology Solutions$1.495B+12.0%
Medical-Surgical Solutions$2.868B+1.0%

Other KPIs

Q4 FY2026
SegmentQ4 FY2026
Adjusted Segment Operating Profit Margin - North American Pharmaceutical1.24%
Adjusted Segment Operating Profit Margin - Oncology & Multispecialty3.03%
Adjusted Segment Operating Profit Margin - Prescription Technology Solutions21.54%
Adjusted Segment Operating Profit Margin - Medical-Surgical Solutions9.45%
Share Repurchases$2.7 billion
Accelerated Share Repurchase Program$2.25 billion
Operating Cash Flow (Q4)$3.4 billion
Diluted Share Count122.7 million

Management tone

Customer optimization hangover → Acquisition pivot → Norway-driven EPS raise → Med-Surg separation timeline → Apollo validation + AI as operating model.

Medical-Surgical's separation has progressed from announced IPO target to externally validated valuation. Q2 FY26 introduced the H2 CY2027 IPO target; Q3 confirmed TSAs went live January 1; this quarter Apollo took a $1.25B strategic minority investment valuing the business at ~$13B EV. Management's framing: "We announced a definitive agreement with Apollo Funds for a $1.25 billion strategic minority investment in medical surgical solutions...valuing NUCO at approximately $13 billion of total enterprise value." The shift is decisive — having an institutional investor sign a valuation marker pre-IPO removes a key uncertainty (will the public market accept the standalone narrative?) and provides a floor for the eventual transaction.

Branded pharma pricing has been reframed from a forward risk to a contained event. A year ago IRA pricing was an open uncertainty; this quarter it materialized in Q4 results — the +3% North American Pharma print reflects the first wave of branded price changes. But management's posture is not defensive: "We successfully navigated the first wave of branded pharmaceutical price changes related to the Inflation Reduction Act...the fundamentals of our business and the strength of our value proposition to manufacturers remain very strong, evidenced by the double-digit adjusted segment operating profit growth in fiscal 26." The FY27 +4–8% revenue guide for North American Pharma codifies the reset rather than fighting it. This is the cleanest signal that IRA is now in the base case rather than a discount.

AI and automation have shifted from productivity narrative to operating model. Q3 referenced 8-touches-to-2-touches automation and 120 more patients per FTE; this quarter management explicitly elevates it to an enterprise-wide operating posture: "We achieved this operating efficiency while simultaneously making targeted investments to modernize our operations through automation and AI-driven capabilities, which we anticipate will accelerate growth, creating enterprise-wide efficiencies." Specific proof points include 1,900+ providers using ambient scribe technology in the US Oncology Network and Montreal Distribution Center robotics. The framing has crossed a threshold — AI is no longer cited as a productivity investment but as the architecture of how McKesson now runs distribution and provider services.

Oncology has moved from designated growth pillar to scaled, mature engine. Q2 made Oncology a discrete segment; Q3 leaned into +15% organic operating profit growth; this quarter management celebrates record platform metrics: "For the US Oncology Network, it's been a remarkable year of growth. We added more than 570 providers in fiscal 26, the largest net increase since 2010." The FY27 +14.5–18.5% revenue guide is lower than FY26's +31% actual, but consistent with a maturing platform where inorganic tailwinds normalize and embedded AI/ambient scribe begins driving productivity per provider rather than provider count.

Capital allocation has been re-anchored to a multi-year compounding story. Where Q1 emphasized $3.4B M&A and $581M buybacks, this quarter management framed the cycle: "During Britt's tenure as CFO, we delivered over 500% increase in shareholder returns. That's over 20% annual growth rate." Combined with the Q3 reference to 1,900bps of ROIC improvement since FY2020, the narrative has become structural — McKesson is selling a durable capital-returns model, not just a quarterly buyback pace.

Recurring themes management leaned on this quarter:

Portfolio clarity through strategic separation (Medical Surgical Solutions carve-out with Apollo minority investment)Oncology/specialty platform at scale—largest provider growth year since 2010AI and automation now embedded operationally (ambient scribe, Montreal Distribution Center robots, inventory planning)GLP-1 established as $53B revenue stream with managed volatilityBiopharma services platform record execution (3.4M patients supported, 120 more per FTE vs prior year)Capital discipline: $5.1B shareholder returns + reinvestment in growth while maintaining 34% ROIC

Risks management surfaced:

Quarter-to-quarter variability in GLP-1 volumes driven by market dynamicsBranded pharmaceutical price changes impact (IRA-related, already materialized in Q4)Prescription Technology Solutions segment revenue/profit trajectory non-linear, subject to drug launch timing, formulary changes, program maturity shiftsDynamic policy environment requiring continued advocacy and capability evolutionMedical Surgical Solutions separation subject to regulatory approvals and customary closing conditions

Q&A highlights

Alan Letts · Bank of America

What is driving slower RXTS segment growth (2.5%-6.5% vs. historical rates)? Is it the 3PL business? What are expectations for GLP-1 growth in the prior authorization business given 4% QoQ decline in distribution?

3PL represents ~55% of RXTS revenue and varies significantly due to product launch timing. GLP-1 showed strong demand in technology services and access programs, reflected in operating profit guidance at upper end of long-term range. Management emphasized strong recognition and demand for access programs despite distribution declines.

3PL represents ~55% of RXTS revenueGLP-1 distribution revenue declined 4% quarter-over-quarterOperating profit guidance at upper end of long-term target rangeAccess programs showing strong demand

Lisa Gill · J.P. Morgan

Break down oncology/multispecialty guidance into organic vs. inorganic. How will Prism and Core Ventures acquisitions contribute to 2027? Were there weather impacts in Q4 beyond January?

Underlying organic growth in oncology/multispecialty is ~13%. Company is lapping Prism and Core Ventures acquisitions from Q1 prior year. Weather impacts in January recovered within quarter and did not impact full Q4 results. Acquisitions performing well with integrations progressing. Organic growth expected to be in middle of long-term target range as acquisitions are lapped.

Organic growth of oncology/multispecialty segment ~13%Lapping Prism and Core Ventures acquisitions completed in prior year Q1$51 million gains in prior year Q2 from equity investment saleGuide at upper end of long-term target range

Erin Wright · Morgan Stanley

What utilization trends are embedded in NAP guidance (described as stable)? Why shift from general specialty product commentary to specifically calling out specialty products to health systems?

Year-over-year utilization growth has been stable and constant for several quarters, growing at very consistent rate over 2-3 years. Specialty products remain strongest growth category with most innovation. Health systems specialty products showing very strong growth in FY26, expected to continue into FY27. Guidance placed at upper end of long-term target range.

Utilization growth stable for several quartersSpecialty category showing most innovation and growthVery strong growth in specialty products to health systems in FY26Guidance at upper end of long-term target range

Brian Tanquillette · Jefferies

What assumptions about GLP-1 demand sustainability are embedded in long-range plan (LRP), specifically regarding access solutions?

GLP-1 distribution revenue has grown mid-20% range for last several years, down sequentially Q4 but still grew 22% in quarter. Solutions for prior authorization and affordability remain high demand. Other adjacent services beyond basic prior auth showing very strong growth. Operating profit growth and segment guidance reflect strength. Category continues to grow with strong need for services.

GLP-1 distribution revenue growth mid-20% range for several years22% growth in Q4 despite sequential declinePrior authorization and affordability solutions in high demandAdjacent services beyond basic prior auth showing very strong growth

Elizabeth Anderson · Evercore ISI

How are you working with customers on Part D biosimilar shifts (Stelara, etc.)? How is biosimilar transition incorporated into FY27 guidance?

Biosimilars viewed as win-win-win for providers, patients, and distributors. Providers make clinical choices; McKesson provides services (GPO, handling) adding value. 89 biosimilars approved, 72 launched, continuing to grow. Part B channel most attractive for McKesson. Services provided across all segments. Biosimilars already factored into guidance.

89 biosimilars approved, 72 launchedBiosimilars win-win-win for providers, patients, distributorsPart B channel identified as most attractiveServices provided across hospitals, retail, mail-order, community

Answers to last quarter's watch list

Q4 free cash flow conversion against the reaffirmed $4.4–$4.8B FY guide. FY26 free cash flow came in at $5.41B, above the $4.4–$4.8B range by $610M–$1.01B, with Q4 alone delivering $3.24B in FCF and $3.4B in operating cash flow. The overshoot helped fund the $4.8B FY26 buyback (vs. ~$2.5B planned), including a $2.25B ASR launched in Q4. Status: Resolved positively.
FY2027 guidance framework — does it preserve the FY26 baseline? Management initiated FY27 adjusted EPS guidance at $43.80–$44.60 (+12–14% YoY), inside the reaffirmed +13–16% long-term band. Excluding the divested Norway business and the Q2 FY26 $51M equity gain, management explicitly stated the implied FY27 EPS growth is +14% to +16% — at the upper end of the long-term target range. Segment revenue guides stepped down meaningfully (North American Pharma to +4–8% from FY26's +11%, Oncology to +14.5–18.5% from +31%, PTS to +2.5–6.5% from +11%) — reverting toward a more typical framing without the acquisition tailwind and lapping favorable FY25 ventures gains. Operating profit growth still leads revenue growth in every distribution segment, preserving the operating leverage story. Status: Resolved in-line — normalized FY27 framework lands at the upper end of long-term targets despite the optical step-down from FY26's +18% comp.
North American Pharmaceutical Q4 revenue growth — does it keep the +10–14% FY guide intact? Q4 came in at +3% YoY (with branded pricing declines reducing growth by ~3%); FY26 landed at +11%, within the +10–14% range. Management attributed Q4 softness to the first wave of IRA branded pricing changes, and the FY27 guide of +4–8% codifies the lower run-rate as structural rather than transient. Status: Resolved positively on the FY guide, with Q4 marking a new structural baseline.
Med-Surg IPO disclosures — carve-out financials and capital structure language. The Apollo minority investment ($1.25B at ~$13B EV) is the most concrete pre-IPO disclosure yet — an institutional valuation marker. Management also confirmed audited carve-out financial statements are complete, a $1B term loan A and $1B revolver were placed in April 2026, and an additional ~$2.25B of term loans are anticipated in the second half of Q1 FY27. H2 CY2027 IPO target reaffirmed. Status: Resolved positively.
GLP-1 sequential growth — does it hold above $14B in Q4? Q4 GLP-1 distribution revenue reached $14B, +22% YoY but -4% sequentially. FY26 GLP-1 revenue totaled $53B (+27% YoY). The sequential decline is consistent with management's flagged quarter-to-quarter variability; the category is established but volatile, and FY27 guidance assumes continued growth with variability. Status: Continue monitoring — Q4 held at $14B but sequential give-back is the first such print in the data series.
Oncology & Multispecialty organic operating profit growth — does it hold above +15%? Per Lisa Gill Q&A reference, organic operating profit growth in oncology/multispecialty was ~13% in Q4, with the segment lapping PRISM and Core Ventures acquisitions. The FY27 segment guide of +14.5–18.5% revenue and +13.5–17.5% operating profit is consistent with that organic baseline plus a residual acquisition tail. Status: Continue monitoring — organic landed slightly below the +15% threshold but management framed it as the post-acquisition normalized rate.

What to watch into next quarter

Q1 FY27 North American Pharmaceutical revenue growth vs. the +4–8% FY27 guide. Watch whether Q1 FY27 prints within +4–8% or shows further weakness; a sub-+4% print would indicate IRA pricing impact is deeper than guided.

Initial Q1 FY27 Oncology & Multispecialty organic disclosure. With PRISM and Core Ventures fully lapped by Q1 FY27, the segment's organic growth becomes visible directly. Watch whether organic growth holds near the ~13% management cited or compresses below low-teens — the latter would weaken the FY27 +14.5–18.5% guide.

Medical-Surgical separation transaction-prep — registration statement filing and final term loan placement. Apollo deal closes "following regulatory approvals," with the ~$2.25B additional term loan expected in the second half of Q1 FY27. Watch for an S-1 filing by Q2 FY27 — absence by the H1 CY2027 mark would put the H2 CY2027 IPO timeline at risk despite the Apollo validation.

GLP-1 trajectory after the Q4 -4% sequential print. Watch whether the $14B Q4 figure proves to be a plateau or whether the category re-accelerates; FY27 guidance assumes continued growth with variability, and a sustained step-down would put consensus FY27 North American Pharma assumptions at risk.

PTS FY27 +2.5–6.5% revenue guide — was Q4's +12% the peak? The decelerating revenue guide against a +11–15% operating profit guide implies aggressive mix shift to higher-margin solutions. Watch whether Q1 FY27 PTS margin holds near the 21.54% Q4 print, which would validate the operating leverage thesis; margin compression would suggest the operating profit guide is at risk.

Pace of the ~$5B FY27 buyback and use of Apollo proceeds. Management has earmarked the Apollo $1.25B investment and Med-Surg financing proceeds principally toward share repurchases, supporting the step-up from ~$2.5B planned in FY26 to ~$5B in FY27 and the 116–118M diluted share guide. Watch whether the cadence holds or whether capital gets redirected to M&A — management explicitly retains that optionality.

Sources

  1. McKesson Q4 FY2026 Earnings Press Release (SEC Exhibit 99.1, period ended March 31, 2026): https://www.sec.gov/Archives/edgar/data/927653/000092765326000066/mck_exhibit991x3312026.htm
  2. McKesson Q4 FY2026 earnings call commentary (CFO and CEO prepared remarks and Q&A as referenced)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.